{"transactions":[{"id":932270,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-01-23T20:25:04.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029."}],"balance_after":1000000,"derivative":{"exercise_price":3.08,"expiration_date":"2036-01-23","underlying":"Common Shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000912282-26-000121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228226000121/form4.xml","form_type":"4"}},{"id":971159,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-12-12T17:07:23.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":true,"shares":739885,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Thye Trust"},"balance_after":739885,"source":{"system":"sec-edgar","filing":"0000912282-25-001407","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225001407/form4.xml","form_type":"4"}},{"id":971158,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-12-12T17:07:23.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":false,"shares":739885,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":255000,"source":{"system":"sec-edgar","filing":"0000912282-25-001407","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225001407/form4.xml","form_type":"4"}},{"id":1103754,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"officer_title":"CEO and CMO"}}],"security":"Warrants","published_at":"2025-06-23T08:43:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":150944,"price":0.125,"value":18868.0,"ownership":{"direct":true},"balance_after":150944,"derivative":{"exercise_price":1.2,"exercise_date":"2025-06-18","expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":150944},"source":{"system":"sec-edgar","filing":"0000912282-25-000695","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225000695/form4.xml","form_type":"4"}},{"id":1103753,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"officer_title":"CEO and CMO"}}],"security":"Common Shares","published_at":"2025-06-23T08:43:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":150944,"price":1.2,"value":181132.8,"ownership":{"direct":true},"balance_after":994885,"source":{"system":"sec-edgar","filing":"0000912282-25-000695","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000091228225000695/form4.xml","form_type":"4"}},{"id":1273808,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-11T17:44:38.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":1200000,"derivative":{"exercise_price":1.6,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001415889-25-003618","document":"form4-02112025_100234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588925003618/form4-02112025_100234.xml","form_type":"4"}},{"id":1417726,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:38:44.000Z","date":"2024-08-30","kind":"purchase","planned":false,"acquired":true,"shares":77000,"price":0.7,"value":53900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive."}],"balance_after":843941,"source":{"system":"sec-edgar","filing":"0001415889-24-022702","document":"form4-09032024_090940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924022702/form4-09032024_090940.xml","form_type":"4"}},{"id":1417725,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:38:44.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":77500,"price":0.69,"value":53475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":766941,"source":{"system":"sec-edgar","filing":"0001415889-24-022702","document":"form4-09032024_090940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924022702/form4-09032024_090940.xml","form_type":"4"}},{"id":1661691,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO AND CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-02T17:50:21.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":1500000,"derivative":{"exercise_price":1.31,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001415889-24-002378","document":"form4-02022024_100215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924002378/form4-02022024_100215.xml","form_type":"4"}},{"id":1677873,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":false,"shares":149999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":450001,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":149999},"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677872,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":false,"shares":90531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":115860,"derivative":{"exercise_price":0.55,"expiration_date":"2022-03-27","underlying":"Common Stock","underlying_shares":90531},"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677871,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":true,"shares":149999,"price":0.94,"value":140999.06,"ownership":{"direct":true},"balance_after":689441,"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1677870,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-17T16:48:28.000Z","date":"2024-01-16","kind":"exercise","planned":false,"acquired":true,"shares":90531,"price":0.55,"value":49792.05,"ownership":{"direct":true},"balance_after":539442,"source":{"system":"sec-edgar","filing":"0001415889-24-001313","document":"form4-01172024_090120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000141588924001313/form4-01172024_090120.xml","form_type":"4"}},{"id":1809915,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-11T16:15:34.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":88000,"price":1.26,"value":110880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":448911,"source":{"system":"sec-edgar","filing":"0001209191-23-045432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919123045432/doc4.xml","form_type":"4"}},{"id":1811991,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-09T18:23:31.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":80000,"price":1.24,"value":99200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":360911,"source":{"system":"sec-edgar","filing":"0001209191-23-045235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919123045235/doc4.xml","form_type":"4"}},{"id":2036090,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-02T18:37:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date."}],"balance_after":600000,"derivative":{"exercise_price":0.94,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-23-006402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919123006402/doc4.xml","form_type":"4"}},{"id":2253419,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-27T17:35:51.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":216322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest monthly, subject to continued service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":280911,"source":{"system":"sec-edgar","filing":"0001209191-22-032675","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919122032675/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-23"}},{"id":2260042,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-23T20:29:04.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":1979650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":1979650,"derivative":{"exercise_price":2.98,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":1979650},"source":{"system":"sec-edgar","filing":"0001209191-22-031515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919122031515/doc4.xml","form_type":"4"}},{"id":2260041,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-23T20:29:04.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":206391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 2,266,500 shares of Novosteo common stock for $0.05 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years."}],"balance_after":206391,"derivative":{"exercise_price":0.55,"expiration_date":"2022-03-27","underlying":"Common Stock","underlying_shares":206391},"source":{"system":"sec-edgar","filing":"0001209191-22-031515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919122031515/doc4.xml","form_type":"4"}},{"id":2260040,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":68903,"kind":"person","name":"Thye Dirk","position":1,"cik":"0001638945","reported_name":"Thye Dirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-23T20:29:04.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":64589,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2022, the Issuer completed acquisition (the \"Merger\") of Novosteo Inc. (\"Novosteo\"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the \"Merger Agreement\"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer."}],"balance_after":64589,"source":{"system":"sec-edgar","filing":"0001209191-22-031515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638945/000120919122031515/doc4.xml","form_type":"4"}}]}